-

09:28:37 AM

HALO Stock News

HALO - Halozyme Therapeutics Inc.

08/09/22 4:01 PM

Nasdaq : HALO

HALOZYME REPORTS SECOND QUARTER 2022 FINANCIAL AND OPERATING RESULTS

Closed Antares Pharma Acquisition, Accelerating High Growth Drug Delivery Leadership and Projected to be Accretive to Revenue for Full Year 2022Second Quarter Revenue Increased 12% YOY to $152.4 million, with GAAP Diluted Earnings per Share of $0.16 and Non-GAAP Diluted Earnings per Share of

RHEA-AI

neutral

08/02/22 12:55 AM

Nasdaq : HALO

Positive Results Announced from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq® with ENHANZE® in Advanced Non-Small Cell Lung Cancer

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche's Phase III IMscin001 study

RHEA-AI

positive

07/26/22 8:30 AM

Nasdaq : HALO

conferences

Halozyme to Report Second Quarter 2022 Financial and Operating Results

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2022 financial and operating results on Tuesday, August 9, 2022, following the close of trading.Halozyme will host a conference call on Tuesday,

RHEA-AI

neutral

06/08/22 8:30 AM

Nasdaq : HALO

conferences

Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the Goldman Sachs 43 rd Annual Global Healthcare Conference being held

RHEA-AI

neutral

06/07/22 8:30 AM

Nasdaq : HALO

Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the commercial launch of TLANDO™ (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency

RHEA-AI

neutral

05/24/22 8:30 AM

Nasdaq : HALO

acquisition

Halozyme Completes Antares Pharma Acquisition

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme") today announced the successful completion of its acquisition of Antares Pharma, Inc. (" Antares").The tender offer for all of the outstanding shares of Antares common stock expired as scheduled at one

RHEA-AI

neutral

05/12/22 8:00 AM

Nasdaq : ATRS, HALO

acquisition

Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the " HSR Act"), applicable to Halozyme's proposed acquisition of Antares Pharma,

RHEA-AI

neutral

05/10/22 4:01 PM

Nasdaq : HALO

Halozyme Reports First Quarter 2022 Results

First Quarter Revenue of $117.3 million, Representing a 32% YOY Increase, with GAAP Diluted Earnings per Share of $0.43 and Non-GAAP Diluted Earnings per Share of $0.47Record Quarterly Royalties in the First Quarter of $69.6 million, Representing 89% Growth over First Quarter 2021Reiterate 2022

RHEA-AI

very positive

05/03/22 2:20 PM

Nasdaq : HALO

conferencesearnings

Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2022 on May 10 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president, and chief executive officer, will lead the call. On the same date,

RHEA-AI

neutral

04/26/22 8:00 AM

Nasdaq : HALO

HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. (" Purchaser"), a cash tender offer to purchase all outstanding shares of common stock of Antares

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

HALO Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.halozyme.com
CeoHelen Torley
Security nameHalozyme Therapeutics Inc.
Issue typecs
SectorManufacturing
Sic code2836
Employees136
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
Address11388 Sorrento Valley Rd
StateCalifornia
CitySan Diego
Zip92121-1345
CountryUS
Phone18587948889

About Halozyme Therapeutics Inc.

Halozyme is a biopharmaceutical company focused on bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego.